Long-term follow-up with bispecific antibodies in follicular lymphoma and LBCL

Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses the long-term follow-up of mosunetuzumab in follicular lymphoma and epcoritamab in large B-cell lymphoma (LBCL). Dr Cheah highlights durable complete responses, indicating the effectiveness of bispecific antibodies in these patients. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.